These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 39029294)
21. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795 [TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer screening in high-risk individuals with germline genetic mutations. DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780 [TBL] [Abstract][Full Text] [Related]
23. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039 [TBL] [Abstract][Full Text] [Related]
24. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384 [TBL] [Abstract][Full Text] [Related]
25. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing. Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154 [TBL] [Abstract][Full Text] [Related]
26. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
27. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Krepline AN; Geurts JL; Akinola I; Christians KK; Clarke CN; George B; Ritch PS; Khan AH; Hall WA; Erickson BA; Griffin MO; Evans DB; Tsai S HPB (Oxford); 2020 Dec; 22(12):1745-1752. PubMed ID: 32354656 [TBL] [Abstract][Full Text] [Related]
28. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB; J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299 [TBL] [Abstract][Full Text] [Related]
29. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
30. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
31. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related]
32. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]